Axe Compute (AGPU) Registration Filing summary

Company overview and business model

• Applies artificial intelligence and a proprietary biobank of 150,000+ tumor samples to optimize oncology drug discovery and development, offering services from early discovery to clinical trials.

• Operates a digital asset treasury strategy focused on Aethir (ATH) tokens, aiming to create a Strategic Compute Reserve and generate yield through staking and related activities.

• PEDAL platform provides early insights for biopharma clients to prioritize oncology portfolios and repurpose failed drug compounds.

Financial performance and metrics

• Held approximately 5.6 billion ATH tokens valued at $107 million as of November 19, 2025, with 3.6 billion locked and 2.0 billion unlocked.

• Closed a $50.77 million cash private placement in September 2025 and received $173.3 million in discounted value of ATH from a crypto PIPE offering.

• Audit reports for 2023 and 2024 include going concern warnings due to recurring losses and accumulated deficit.

Use of proceeds and capital allocation

• Proceeds from warrant exercises will be used for the Treasury Strategy, general corporate, and working capital purposes.

• Net proceeds from the September offerings are primarily allocated to acquiring ATH tokens and supporting the Treasury Strategy.